Activity of T-DM1 in Her2-positive breast cancer brain metastases

Clinical and Experimental Metastasis

Volumn 32, Issue 7, 2015, Pages 729-737

  Bartsch, Rupert ^a   Berghoff, Anna S ^a   Vogl, Ursula ^b   Rudas, Margaretha ^a   Bergen, Elisabeth ^a   Dubsky, Peter ^a   Dieckmann, Karin ^a   Pinker, Katja ^a   Bago Horvath, Zsuzsanna ^a   Galid, Arik ^c   Oehler, Leopold ^b   Zielinski, Christoph C ^a   Gnant, Michael ^a   Steger, Guenther G ^a   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Medicine   (Austria)

^c HANUSCH HOSPITAL   (Austria)

Author keywords

Brain metastases; Breast cancer; Her2 positive; Systemic therapy; T DM1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA GLUTAMYLTRANSFERASE; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG EFFICACY; EDEMA; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; RASH; SIDE EFFECT; SYMPTOM; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; VERTIGO; XEROSTOMIA; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAYTANSINE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84942372167     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9740-3     Document Type: Article

References (23)

1. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero JM, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14(1):64–71. doi:10.1016/S1470-2045(12)70432-1
2. Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG (2009) Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 9:367. doi:10.1186/1471-2407-9-367
3. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG (2012) Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 106(1):25–31. doi:10.1038/bjc.2011.531
4. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977. doi:10.1002/cncr.11436
5. Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106(3):440–446. doi:10.1038/bjc.2011.597
6. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044. doi:10.1016/S1470-2045(09)70263-3
7. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91(4):639–643. doi:10.1038/sj.bjc.6601970
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
9. Feyer P, Sautter-Bihl ML, Budach W, Dunst J, Haase W, Harms W, Sedlmayer F, Souchon R, Wenz F, Sauer R, Breast Cancer Expert Panel of the German Society of Radiation O (2010) DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlentherapie und Onkologie 186(2):63–69. doi:10.1007/s00066-010-2100-y
10. Galea I, Bechmann I, Perry VH (2007) What is immune privilege (not)? Trends Immunol 28(1):12–18. doi:10.1016/j.it.2006.11.004
11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529
12. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAdagger. Annals Oncol 26(1):113–119. doi:10.1093/annonc/mdu486
13. Lin N, Lee E, Aoyama H, Barani I, Barboriak D, Baumert B, Bendszus M, Brown P, Camidge D, Chang S, Dancey J, de Vries E, Gaspar L, Harris G, Hodi F, Kalkanis S, Linskey M, Macdonald D, Margolin K, Mehta M, Schiff D, Soffietti R, Suh J, van den Bent M, Vogelbaum M, Wen P (2015) Proposed Response Assessment Criteria for Brain Metastases: Response Assessment in Neuro-Oncology (RANO) Working Group. The Lancet Oncology: in press
14. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 15(4):1452–1459. doi:10.1158/1078-0432.CCR-08-1080
15. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13(6):1648–1655. doi:10.1158/1078-0432.CCR-06-2478
16. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY, Response Assessment in Neuro-Oncology g (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. The Lancet Oncology 14 (10): e396–406. doi:10.1016/S1470-2045(13)70311-5
17. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12):1993–1999. doi:10.1200/JCO.2007.12.3588
18. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crino L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals Oncol 22(3):625–630. doi:10.1093/annonc/mdq434
19. Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD (2015) Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-Oncol 17(2):289–295. doi:10.1093/neuonc/nou141
20. Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58(4):832–839
21. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, Group ES (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Eng J Med 367 (19):1783–1791. doi:10.1056/NEJMoa1209124
22. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167(4):913–920. doi:10.1016/S0002-9440(10)61180-7
23. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical O, College of American P (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (1):118–145. doi:10.1200/JCO.2006.09.2775